JP2017507155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507155A5 JP2017507155A5 JP2016555590A JP2016555590A JP2017507155A5 JP 2017507155 A5 JP2017507155 A5 JP 2017507155A5 JP 2016555590 A JP2016555590 A JP 2016555590A JP 2016555590 A JP2016555590 A JP 2016555590A JP 2017507155 A5 JP2017507155 A5 JP 2017507155A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- ctla
- composition according
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims 12
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 11
- 229940127084 other anti-cancer agent Drugs 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 5
- 238000009097 single-agent therapy Methods 0.000 claims 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 230000008595 infiltration Effects 0.000 claims 4
- 238000001764 infiltration Methods 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 229960000639 pazopanib Drugs 0.000 claims 4
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 4
- 206010061818 Disease progression Diseases 0.000 claims 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 3
- 102100022338 Integrin alpha-M Human genes 0.000 claims 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 3
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000005750 disease progression Effects 0.000 claims 3
- 210000000066 myeloid cell Anatomy 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 229960001796 sunitinib Drugs 0.000 claims 3
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 3
- 230000001988 toxicity Effects 0.000 claims 3
- 231100000419 toxicity Toxicity 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 102000043321 human CTLA4 Human genes 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461948428P | 2014-03-05 | 2014-03-05 | |
| US61/948,428 | 2014-03-05 | ||
| US201461977318P | 2014-04-09 | 2014-04-09 | |
| US61/977,318 | 2014-04-09 | ||
| US201461992729P | 2014-05-13 | 2014-05-13 | |
| US61/992,729 | 2014-05-13 | ||
| US201462005600P | 2014-05-30 | 2014-05-30 | |
| US62/005,600 | 2014-05-30 | ||
| PCT/US2015/018727 WO2015134605A1 (en) | 2014-03-05 | 2015-03-04 | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019152086A Division JP2020007331A (ja) | 2014-03-05 | 2019-08-22 | 抗ｐｄ−１抗体と他の抗癌剤の組合せを使用する腎癌の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017507155A JP2017507155A (ja) | 2017-03-16 |
| JP2017507155A5 true JP2017507155A5 (https=) | 2018-04-12 |
Family
ID=52686508
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555590A Pending JP2017507155A (ja) | 2014-03-05 | 2015-03-04 | 抗ｐｄ−１抗体と他の抗癌剤の組合せを使用する腎癌の処置 |
| JP2019152086A Pending JP2020007331A (ja) | 2014-03-05 | 2019-08-22 | 抗ｐｄ−１抗体と他の抗癌剤の組合せを使用する腎癌の処置 |
| JP2022007365A Pending JP2022058698A (ja) | 2014-03-05 | 2022-01-20 | 抗ｐｄ－１抗体と他の抗癌剤の組合せを使用する腎癌の処置 |
| JP2024163901A Pending JP2024178325A (ja) | 2014-03-05 | 2024-09-20 | 抗ｐｄ－１抗体と他の抗癌剤の組合せを使用する腎癌の処置 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019152086A Pending JP2020007331A (ja) | 2014-03-05 | 2019-08-22 | 抗ｐｄ−１抗体と他の抗癌剤の組合せを使用する腎癌の処置 |
| JP2022007365A Pending JP2022058698A (ja) | 2014-03-05 | 2022-01-20 | 抗ｐｄ－１抗体と他の抗癌剤の組合せを使用する腎癌の処置 |
| JP2024163901A Pending JP2024178325A (ja) | 2014-03-05 | 2024-09-20 | 抗ｐｄ－１抗体と他の抗癌剤の組合せを使用する腎癌の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20170088626A1 (https=) |
| EP (2) | EP3114144A1 (https=) |
| JP (4) | JP2017507155A (https=) |
| KR (3) | KR20160119867A (https=) |
| CN (2) | CN106255510A (https=) |
| WO (1) | WO2015134605A1 (https=) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2593027T3 (es) | 2009-03-30 | 2016-12-05 | Eisai R&D Management Co., Ltd. | Composición liposomal |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| WO2015088847A1 (en) * | 2013-12-11 | 2015-06-18 | Glaxosmithkline Llc | Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| EA201691376A1 (ru) | 2014-02-04 | 2017-01-30 | Пфайзер Инк. | Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| US20160158360A1 (en) * | 2014-12-05 | 2016-06-09 | Genentech, Inc. | Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists |
| NZ733854A (en) | 2015-02-26 | 2022-07-01 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| CA2978311A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and eribulin for treating cancer |
| EP3067062A1 (en) * | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| US11078278B2 (en) | 2015-05-29 | 2021-08-03 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| MA44594B1 (fr) | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
| PH12017501857B1 (en) | 2015-06-16 | 2024-01-17 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| KR102055396B1 (ko) | 2015-08-11 | 2019-12-12 | 우시 바이올로직스 (케이만) 인코포레이티드 | 신규한 항-pd-1 항체 |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| WO2017049199A1 (en) | 2015-09-16 | 2017-03-23 | Board Of Regents, University Of Texas System | Combination of topoisomerase-i inhibitors with immunotherapy in the treatment of cancer |
| CN108136010A (zh) * | 2015-10-08 | 2018-06-08 | 宏观基因有限公司 | 用于治疗癌症的联合疗法 |
| WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| WO2017176925A1 (en) | 2016-04-05 | 2017-10-12 | Bristol-Myers Squibb Company | Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| US12029724B2 (en) | 2016-04-28 | 2024-07-09 | Eisai R&D Management Co., Ltd. | Method for inhibiting tumor growth |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| KR20190062515A (ko) | 2016-10-06 | 2019-06-05 | 화이자 인코포레이티드 | 암의 치료를 위한 아벨루맙의 투약 용법 |
| TWI764943B (zh) * | 2016-10-10 | 2022-05-21 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途 |
| IL265921B2 (en) | 2016-10-14 | 2024-05-01 | Prec Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| WO2018106862A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| JP7106538B2 (ja) | 2016-12-07 | 2022-07-26 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
| PT3565844T (pt) | 2017-01-09 | 2023-05-02 | Tesaro Inc | Métodos de tratamento de cancro com anticorpos anti-pd-1 |
| CN106729705B (zh) * | 2017-01-23 | 2018-04-06 | 河南省华隆生物技术有限公司 | 一种药物组合物及其应用 |
| HUE068810T2 (hu) | 2017-02-15 | 2025-01-28 | Taiho Pharmaceutical Co Ltd | Gyógyászati készítmény |
| EP3366703B1 (en) * | 2017-02-28 | 2019-04-03 | Ralf Kleef | Immune checkpoint therapy with hyperthermia |
| CN110546277B (zh) | 2017-03-01 | 2024-06-11 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| MA50251A (fr) * | 2017-09-08 | 2021-06-02 | Taiho Pharmaceutical Co Ltd | Agent antitumoral et potentialisateur d'effet antitumoral |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| KR102089241B1 (ko) * | 2018-02-05 | 2020-03-16 | 한국과학기술원 | 암 환자에서 면역 치료 효과를 예측하는 방법 |
| PL3759109T3 (pl) | 2018-02-26 | 2024-03-04 | Gilead Sciences, Inc. | Podstawione związki pirolizyny jako inhibitory replikacji hbv |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| EP3842070A4 (en) | 2018-07-18 | 2022-04-20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | DRUG COMBINATION OF QUINOLINE DERIVATIVE AND ANTIBODY |
| CN113861295B (zh) * | 2018-07-20 | 2024-05-24 | 厦门大学 | 抗pd-1抗体及其用途 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| MX2021004348A (es) * | 2018-10-18 | 2021-05-28 | Genentech Inc | Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide. |
| TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| US20220000858A1 (en) * | 2018-11-05 | 2022-01-06 | Aveo Pharmaceuticals, Inc. | Use of tivozanib to treat subjects with refractory cancer |
| AU2020212767B2 (en) | 2019-01-25 | 2025-01-30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combined pharmaceutical composition for treating tumor |
| EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| KR102707808B1 (ko) | 2019-03-07 | 2024-09-19 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| US11083705B2 (en) * | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN119770638A (zh) | 2019-09-30 | 2025-04-08 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| US20220378776A1 (en) * | 2019-11-04 | 2022-12-01 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | Drug combination of quinoline derivative and pd-1 monoclonal antibody |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| CA3171250A1 (en) | 2020-03-10 | 2021-09-16 | E. Lynne KELLEY | Methods for treating neutropenia |
| US11718637B2 (en) | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| AR122043A1 (es) * | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | Dosificación y administración del anticuerpo anti-ctla-4 activable |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| JP7673255B2 (ja) | 2021-06-11 | 2025-05-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023220558A1 (en) * | 2022-05-09 | 2023-11-16 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Combination of curaxins and immune checkpoint inhibitors for treating cancer |
| KR20240068809A (ko) | 2022-10-31 | 2024-05-20 | 재단법인 아산사회복지재단 | Ifitm3 억제제를 포함하는 신장암 예방 또는 치료용 약학적 조성물 |
| WO2024138019A1 (en) * | 2022-12-23 | 2024-06-27 | Actinium Pharmaceuticals, Inc. | Her3 radioimmunotherapy for the treatment of solid cancers |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| CN120501749A (zh) * | 2025-05-28 | 2025-08-19 | 皖南医学院 | Prmt5抑制剂或其与抗pd-1抗体联合在制备治疗肾癌的药物中的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| RU2494107C2 (ru) * | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| JP2009543810A (ja) * | 2006-07-13 | 2009-12-10 | ザイモジェネティクス， インコーポレイテッド | インターロイキン２１およびチロシンキナーゼ阻害剤の併用治療の方法 |
| US9090693B2 (en) * | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| US8460886B2 (en) * | 2008-07-04 | 2013-06-11 | Ono Pharmaceutical Co., Ltd. | Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers |
| CN102203132A (zh) * | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| CA2828940C (en) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| JP6240600B2 (ja) | 2011-07-24 | 2017-11-29 | キュアテク リミテッド | ヒト化免疫モノクローナル抗体の変異体 |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| CN103242448B (zh) * | 2013-05-27 | 2015-01-14 | 郑州大学 | 一种全人源化抗pd-1单克隆抗体及其制备方法和应用 |
| CN103536917B (zh) * | 2013-10-30 | 2015-03-11 | 苏州丁孚靶点生物技术有限公司 | 干扰素在治疗肿瘤中的用途及相关的产品和方法 |
| EA201691376A1 (ru) * | 2014-02-04 | 2017-01-30 | Пфайзер Инк. | Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака |
-
2015
- 2015-03-04 EP EP15710681.6A patent/EP3114144A1/en not_active Withdrawn
- 2015-03-04 KR KR1020167027017A patent/KR20160119867A/ko not_active Ceased
- 2015-03-04 CN CN201580023210.5A patent/CN106255510A/zh active Pending
- 2015-03-04 JP JP2016555590A patent/JP2017507155A/ja active Pending
- 2015-03-04 KR KR1020227030567A patent/KR20220127940A/ko not_active Ceased
- 2015-03-04 CN CN202111631085.XA patent/CN114432440A/zh active Pending
- 2015-03-04 KR KR1020247031210A patent/KR20240144452A/ko not_active Ceased
- 2015-03-04 EP EP19167467.0A patent/EP3572430A3/en active Pending
- 2015-03-04 US US15/122,827 patent/US20170088626A1/en not_active Abandoned
- 2015-03-04 WO PCT/US2015/018727 patent/WO2015134605A1/en not_active Ceased
-
2019
- 2019-05-06 US US16/404,593 patent/US20190263923A1/en not_active Abandoned
- 2019-08-22 JP JP2019152086A patent/JP2020007331A/ja active Pending
-
2022
- 2022-01-20 JP JP2022007365A patent/JP2022058698A/ja active Pending
- 2022-05-04 US US17/662,034 patent/US20220389110A1/en not_active Abandoned
-
2024
- 2024-09-20 JP JP2024163901A patent/JP2024178325A/ja active Pending
-
2025
- 2025-04-07 US US19/172,371 patent/US20250297028A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507155A5 (https=) | ||
| Aglietta et al. | A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer | |
| CN110475571B (zh) | 细胞免疫疗法前细胞毒性预调理的替代 | |
| JP2019503387A5 (https=) | ||
| Cho et al. | Bispecific antibodies in multiple myeloma treatment: A journey in progress | |
| KR102705821B1 (ko) | 항암제 | |
| RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
| JP2018500332A5 (https=) | ||
| TW202228777A (zh) | 對抗pd-1及pd-l1之拮抗劑與輻射療法組合之治療方法 | |
| KR102902532B1 (ko) | 면역절제 요법 | |
| JP2025185043A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| JP2012102122A5 (https=) | ||
| EP3551629B1 (en) | Oxabicycloheptanes for modulation of immune response | |
| JP2014511383A5 (https=) | ||
| WO2014142220A1 (ja) | 抗腫瘍剤 | |
| TW201922282A (zh) | Ｐｄ-１抗體和表觀遺傳調節劑聯合在製備治療腫瘤的藥物中的用途 | |
| HRP20250113T1 (hr) | Režim doziranja za gp100-specifični tcr - anti-cd3 scfv fuzijski protein | |
| Rizvi et al. | A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered with ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with select advanced solid tumors | |
| US11110105B2 (en) | Compounds, composition and uses thereof for treating cancer | |
| CA3214753A1 (en) | Dosing of bispecific t cell engager | |
| WO2021247473A1 (en) | Methods of treatment using icam-modulating agents | |
| Khot et al. | A Phase 1, Open-Label, Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of a first in class Pol1 inhibitor (CX-5461) in Patients with Advanced Haematologic Malignancies (HM) | |
| Müller | Immunotherapy in Multiple Myeloma: Recent Developments in Monoclonal Antibodies, Bispecifics and Antibody-Drug Conjugates | |
| CA3046515C (en) | Oxabicycloheptanes for modulation of immune response | |
| WO2023210042A1 (ja) | Ｉｌ－３４を発現する腫瘍を治療および／または予防するための医薬 |